The latest report by IMARC Group, titled “Macular Degeneration Treatment Market Report by Type (Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration), Stage of Disease (Early Stage, Intermediate Stage, Late Stage), Route of Administration (Intravenous Route, Intravitreal Route), End User (Hospitals, Ambulatory Surgical Center, and Others), and Region 2026-2034,” finds that the global macular degeneration treatment market size reached USD 10.4 Billion in 2025. Macular degeneration is a neurodegenerative eye disorder caused by deterioration of the macula, the part of the retina that controls sharp, straight-ahead vision. It leads to blurred or complete vision loss in the center of the visual field. The condition is generally characterized by blind or blurry spots in the field of vision, visual distortions, and the inability to see in low light conditions. It can be treated by various therapeutic techniques, such as anti-angiogenic drugs, photodynamic laser therapies, contact lenses, and transitional lenses. In recent years, macular degeneration treatment has gained immense traction across the globe as timely treatment can help improve vision and reduce the risks of developing chronic or permanent blindness. 

Global Macular Degeneration Treatment Market Trends:

The rising incidences of retinal disorders and the surging awareness regarding available treatment options among the masses represent the primary factors driving the market growth. Besides this, since macular degeneration usually affects older adults, the expanding geriatric population is another major growth-inducing factor. Additionally, there has been a widespread prevalence of obesity and cardiovascular diseases (CVDs) due to sedentary lifestyles, changing dietary patterns, and unhealthy habits like smoking. In line with this, prolonged screen time owing to the growing usage of smartphones, laptops, and television is contributing to the development of eye conditions, which has augmented the demand for macular degeneration treatment. Furthermore, the leading players are extensively investing in research and development (R&D) activities to develop innovative and effective drugs. Along with this, the introduction of retinal gene therapies that involve injecting adeno-associated virus (AAV) into the body to prevent the growth of abnormal blood vessels has propelled the market growth. Other factors, including the rising popularity of biosimilars, increasing approvals of novel drugs, favorable government initiatives, improving healthcare infrastructure, and technological advancements, are also providing a positive thrust to the market growth. Looking forward, IMARC Group expects the market value to reach USD 16.2 Billion by 2034, growing at a CAGR of 4.87% during the forecast period (2026-2034).

Market Summary:

• Based on the type, the market has been bifurcated into dry and wet age-related macular degeneration. 
• The market has been segregated based on the stage of disease into early, intermediate, and late stages. 
• On the basis of the route of administration, the market has been classified as intravenous and intravitreal routes. 
• Based on the end user, the market has been divided into hospitals, ambulatory surgical center, and others. 
• Region-wise, the market has been segmented into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa. 
• The competitive landscape of the market has also been examined, with some of the key players being Alcon Inc., Apellis Pharmaceuticals, Inc., Astellas Pharma US, Inc., Bausch + Lomb, Bayer Consumer Care AG, F. Hoffmann-La Roche Ltd, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc., Regeneron Pharmaceuticals Inc., Regenxbio Inc., Samsung Bioepis, etc.

Report Coverage:

Report Features	Details
Base Year of the Analysis	2025
Historical Period	2020-2025
Forecast Period	2026-2034
Units	Billion USD
Segment Coverage	Type, Stage of Disease, Route of Administration, End User, Region
Region Covered	Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered	United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered	Alcon Inc., Apellis Pharmaceuticals, Inc., Astellas Pharma US, Inc., Bausch + Lomb, Bayer Consumer Care AG, F. Hoffmann-La Roche Ltd, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc., Regeneron Pharmaceuticals Inc., Regenxbio Inc., Samsung Bioepis, etc.
Customization Scope	10% Free Customization
Post-Sale Analyst Support	10-12 Weeks
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
30 N Gould St, Ste R
Sheridan, WY 82801, USA
Website: //czldyw.com/
Email: 高清体育直播:[email protected]
Americas: +1 631 791 1145 | Euro♔pe & Africa: +44-753-713-2163 | Asia: +91-120-433-0800